Lonza Signs Agreement with Index Ventures for Biological Products

January 17, 2014
BioPharm International Editors

Lonza signs an agreement with Index Ventures for the development and manufacture of biologics for portfolio companies.

Lonza, a custom biologics manufacturing organization and Index Ventures, a venture capital investment firm, have signed an agreement for process development and cGMP production for all biological products in the portfolio of companies where Index is the major investor. Over the course of the agreement, additional development and manufacturing projects will be added to the product list, as future investments are made by Index.

Source: Lonza

Related Content:

Industry News | News